Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Barry James Maurer is active.

Publication


Featured researches published by Barry James Maurer.


Methods in molecular medicine | 2005

Evaluating Response to Antineoplastic Drug Combinations in Tissue Culture Models

C. Patrick Reynolds; Barry James Maurer

The mainstay of clinical antineoplastic chemotherapy is multiagent combinations, most of which were developed empirically. Because of the desire to speed research and decrease costs, there is increasing interest in moving new drugs into clinical trials in potentially active combinations based on preclinical testing data. Different mathematical models have been proposed for evaluating drug interactions, which can be classified as synergistic (combinations demonstrating greater than the additive activity expected from each agent alone), additive, or antagonistic (drugs showing less activity in combination than expected from the sum of each agent alone). Here, we briefly review some of the principles for testing cytotoxic drug interactions. We focus this review on application of the Combination Index method (as developed by Chou and colleagues) in the evaluation of drug interactions in cell culture assays.


Investigative Ophthalmology & Visual Science | 2008

N-(4-hydroxyphenyl) Retinamide Augments Laser-Induced Choroidal Neovascularization in Mice

Parameswaran G. Sreekumar; Jiehao Zhou; Joonhong Sohn; Christine Spee; Stephen J. Ryan; Barry James Maurer; Ram Kannan; David R. Hinton

PURPOSE To evaluate the effect of N-4-hydroxyphenyl retinamide (4-HPR) on experimental laser-induced choroidal neovascularization (CNV) and on the expression and secretion of relevant growth factors by cultured human retinal pigment epithelial (RPE) cells. METHODS CNV was induced by laser photocoagulation in C57BL/6 mice. 4-HPR (0.2 or 1 mg) or vehicle, was injected intraperitoneally twice daily for 14 days. Plasma and tissue levels of 4-HPR were measured by HPLC. CNV was evaluated by fluorescein angiography, histology, and quantitative confocal analysis of isolectin B4 histochemistry on days 7 and 14. Induction of apoptosis and expression and secretion of growth factors was studied in 4-HPR-treated RPE cultures. RESULTS Mice treated with 4-HPR exhibited time- and dose-dependent increases in plasma and tissue 4-HPR levels. CNV lesions showed increased volume with increased vascular leakage and contained fewer lesion-associated RPE in treated versus untreated mice. Treatment of nonpolarized RPE cultures with 4-HPR in the presence of serum resulted in RPE apoptosis; however, apoptosis was minimal in similarly treated highly polarized RPE. Treatment of RPE cells with 4-HPR resulted in the upregulation of VEGF-A and -C (P < 0.05) and Ang-1 (P < 0.01) mRNA and increased secretion of VEGF-A and -C (P < 0.05), whereas pigment epithelium-derived growth factor (PEDF) and thrombospondin (TSP)-1 mRNA expression and secretion were downregulated (P < 0.05). CONCLUSIONS 4-HPR increases lesion size and leakage in laser-induced CNV and is associated with the upregulation of key proangiogenic factors and the downregulation of antiangiogenic factors. Consistent with the preferential loss of RPE in CNV lesions in vivo, 4-HPR induces apoptosis of nonpolarized RPE in the presence of serum.


Archive | 2004

Oral compositions of fenretinide having increased bioavailability and methods of using the same

Barry James Maurer; Charles Patrick Reynolds; David W. Yesair; Robert Travis McKee; Stephen W. Burgess; Walter A. Shaw


Molecular Pharmacology | 1999

Growth of Human Tumor Cells in Macroporous Microcarriers Results in p53-Independent, Decreased Cisplatin Sensitivity Relative to Monolayers

Barry James Maurer; Michael A. Ihnat; Cindy Morgan; Janice Pullman; Craig O'Brien; Steven W. Johnson; Janet S. Rasey; Marilyn M. Cornwell


Archive | 2004

PPMP as a ceramide catabolism inhibitor for cancer treatment

Barry James Maurer; Charles Patrick Reynolds


Archive | 2005

Oral compositions having increased bioavailability and methods of using the same

Barry James Maurer; Charles Patrick Reynolds; David W. Yesair; Robert Travis McKee; Stephen W. Burgess; Walter A. Shaw


Cancer Research | 2004

Improved oral fenretinide delivery with novel Lym-X-Sorb™ organized lipid complex

Barry James Maurer; T. Frgala; Bee-Chun Sun; J. Vlckova; C. Reynolds; D. W. Yesair; S. W. Burgess; R. T. McKee; W. A. Shaw


Cancer Research | 2004

Uptake and metabolism of safingol in human neuroblastoma and leukemia cell lines

Hongtao Wang; Guoying Kong; C. Patrick Reynolds; Barry James Maurer


Archive | 2010

Compositions et méthodes de traitement de troubles hyperprolifératifs

Barry James Maurer; Charles Patrick Reynolds


Archive | 2010

Zusammensetzungen und Verfahren zur Behandlung hyperproliferativer Erkrankungen

Barry James Maurer; Charles Patrick Reynolds

Collaboration


Dive into the Barry James Maurer's collaboration.

Top Co-Authors

Avatar

C. Patrick Reynolds

Texas Tech University Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Shanker Gupta

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

B. Rao Vishnuvajjala

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

Charles Patrick Reynolds

Texas Tech University Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

David W. Yesair

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

Robert Travis McKee

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

Stephen W. Burgess

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

Walter A. Shaw

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

Hongtao Wang

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Myles Cabot

University of Southern California

View shared research outputs
Researchain Logo
Decentralizing Knowledge